Who
David S. Snyder
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Coya Therapeutics; Chief Financial Officer, Exicure; EVP and CFO, Cellular Dynamics International.
In numbers
- Trades disclosed
- 18
- Buys
- 3
- Sells
- 0
- Bought
- $38K
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 30 Jul 2013
- Last trade
- 22 Jan 2026
- Last filed
- 26 Jan 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,041 at $0.00 | filing |
| 22 Jan 2026filed 26 Jan 2026 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,041 at $0.00 | filing |
| 9 Jan 2025filed 13 Jan 2025 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,562 at $0.00 | filing |
| 14 Nov 2024filed 14 Nov 2024 | COYA Coya TherapeuticsBiotechnology | SEC FORM 4 Bought | $13K1,800 at $7.19 | filing |
| 3 Jun 2024filed 5 Jun 2024 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,596 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —81,819 at $0.00 | filing |
| 27 Feb 2023filed 1 Mar 2023 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —115,000 at $0.00 | filing |
| 3 Jan 2023filed 4 Jan 2023 | COYA Coya Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code P | —3,500 | filing |
| 3 Jan 2023filed 4 Jan 2023 | COYA Coya TherapeuticsBiotechnology | SEC FORM 4 Bought | —7,000 | filing |
| 13 Mar 2020filed 16 Mar 2020 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —230,200 at $0.00 | filing |
| 12 Mar 2020filed 16 Mar 2020 | XCUR ExicureBiotechnology | SEC FORM 4 Bought | $26K18,248 at $1.40 | filing |
| 28 Feb 2019filed 1 Mar 2019 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —250,000 at $0.00 | filing |
| 2 Aug 2018filed 3 Aug 2018 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 26 Sep 2017filed 28 Sep 2017 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —374,133 at $0.00 | filing |
| 26 Sep 2017filed 28 Sep 2017 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,859 at $0.00 | filing |
| 26 Sep 2017filed 28 Sep 2017 | XCUR Exicureoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,412 at $0.00 | filing |
| 6 Mar 2014filed 11 Mar 2014 | Cellular Dynamics Internationaloption or derivative | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 30 Jul 2013filed 1 Aug 2013 | Cellular Dynamics Internationaloption or derivative | SEC FORM 4 Code A | —43,077 at $0.00 | filing |
News
CareDx (NASDAQ:CDNA) vs. Exicure (NASDAQ:XCUR) Head-To-Head ComparisonXCUR · dailypolitical.com · 20 Oct 2026Exicure (NASDAQ:XCUR) & Immatics (NASDAQ:IMTX) Head-To-Head AnalysisXCUR · tickerreport.com · 11 Oct 2026Madrigal Pharmaceuticals (NASDAQ:MDGL) & Coya Therapeutics (NASDAQ:COYA) Critical ContrastCOYA · themarketsdaily.com · 9 Oct 2026
0 headlines in the last 90 days name David S. Snyder; 3 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.